Fig. 5. Chemical structures of rigosertib (36), olaparib (37), axitinib (38), cisplatin (39) and mitomycin C (40) that failed to meet the phase III PC endpoint or failed at phase II due to toxicity issues. Sunitinib (41) was approved to treat patients with progressive, well-differentiated pNETs in 2011.61.